Description

Simple

Clinical

Overview

Vicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of HIV-1. This pyrimidine based drug inhibits the interaction of HIV-1 with CCR5, preventing viral entry into cells. This drug was developed by Schering-Plough.

Pharmacology

Indication

Investigated for use/treatment in HIV infection and viral infection.

Pharmacodynamic

Information currently not available.

Mechanism of action

Vicriviroc is a once daily oral inhibitor of CCR5. It noncompetitively binds to a hydrophobic pocket between transmembrance helices by the extracellular side of CCR5. This allosteric antagonism causes a conformational change in the protein preventing binding of gp120 to CCR5. This prevents the entry... Read more

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Vicriviroc
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
(R)-warfarin
The metabolism of (R)-warfarin can be decreased when combined with Vicriviroc.
(S)-Warfarin
The metabolism of (S)-Warfarin can be decreased when combined with Vicriviroc.
Abatacept
The metabolism of Vicriviroc can be increased when combined with Abatacept.
Abiraterone
The metabolism of Vicriviroc can be decreased when combined with Abiraterone.
Acalabrutinib
The metabolism of Vicriviroc can be decreased when combined with Acalabrutinib.
Acenocoumarol
The metabolism of Acenocoumarol can be decreased when combined with Vicriviroc.
Acetohexamide
The metabolism of Vicriviroc can be decreased when combined with Acetohexamide.
Acetyl sulfisoxazole
The metabolism of Vicriviroc can be decreased when combined with Acetyl sulfisoxazole.
Acetylsalicylic acid
The metabolism of Vicriviroc can be decreased when combined with Acetylsalicylic acid.
Adalimumab
The metabolism of Vicriviroc can be increased when combined with Adalimumab.
Afelimomab
The metabolism of Vicriviroc can be increased when combined with Afelimomab.
Agomelatine
The metabolism of Vicriviroc can be decreased when combined with Agomelatine.
Alfentanil
The metabolism of Alfentanil can be decreased when combined with Vicriviroc.
Alosetron
The metabolism of Vicriviroc can be decreased when combined with Alosetron.
Alpelisib
The serum concentration of Vicriviroc can be decreased when it is combined with Alpelisib.
Alprazolam
The metabolism of Vicriviroc can be decreased when combined with Alprazolam.
Ambrisentan
The metabolism of Vicriviroc can be decreased when combined with Ambrisentan.
Aminophenazone
The metabolism of Vicriviroc can be decreased when combined with Aminophenazone.
Amiodarone
The metabolism of Vicriviroc can be decreased when combined with Amiodarone.
Amitriptyline
The metabolism of Vicriviroc can be decreased when combined with Amitriptyline.
3 References
  1. 1 . Idemyor V: Human immunodeficiency virus (HIV) entry inhibitors (CCR5 specific blockers) in development: are they the next novel therapies? HIV Clin Trials. 2005 Sep-Oct;6(5):272-7.PubMed: 16306033
  2. 2 . Emmelkamp JM, Rockstroh JK: CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature. Eur J Med Res. 2007 Oct 15;12(9):409-17.PubMed: 17933722
  3. 3 . Ghosal A, Ramanathan R, Yuan Y, Hapangama N, Chowdhury SK, Kishnani NS, Alton KB: Identification of human liver cytochrome P450 enzymes involved in biotransformation of vicriviroc, a CCR5 receptor antagonist. Drug Metab Dispos. 2007 Dec;35(12):2186-95. Epub 2007 Sep 7.PubMed: 17827338